TIBET WEIXINKANG MEDICINE CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.76 CNY | +3.30% |
|
+13.32% | -16.01% |
| Sales 2022 | 1.4B 193M 264M | Sales 2023 | 1.32B 183M 250M | Capitalization | 4.54B 626M 856M |
|---|---|---|---|---|---|
| Net income 2022 | 177M 24.43M 33.39M | Net income 2023 | 214M 29.53M 40.38M | EV / Sales 2022 | 4.38 x |
| Net cash position 2022 | 801M 110M 151M | Net cash position 2023 | 887M 122M 167M | EV / Sales 2023 | 2.76 x |
| P/E ratio 2022 |
38.8
x | P/E ratio 2023 |
20.9
x | Employees | 656 |
| Yield 2022 |
1.48% | Yield 2023 |
-
| Free-Float | 22.01% |
More Fundamentals
* Assessed data
More news
| 1 day | +3.30% | ||
| 1 week | +13.32% | ||
| Current month | +4.41% | ||
| 1 month | +5.93% | ||
| 3 months | -4.26% | ||
| 6 months | -13.52% | ||
| Current year | -16.01% |
1 week
7.66
9.03
1 month
7.249.03
Current year
6.3010.73
1 year
6.3015.96
3 years
6.3018.30
5 years
6.3018.30
10 years
6.3027.58
| Managers | Title | Age | Since |
|---|---|---|---|
Feng Liu
FOU | Founder | 50 | 06-03-16 |
Yong Zhang
CEO | Chief Executive Officer | 51 | 13-07-05 |
Yan Xia Zheng
DFI | Director of Finance/CFO | 45 | 10-09-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yan Ping Zhao
BRD | Director/Board Member | 62 | 21-12-21 |
Yong Zhang
CEO | Chief Executive Officer | 51 | 13-07-05 |
Feng Liu
FOU | Founder | 50 | 06-03-16 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 8.76 | +3.30% | 9,411,400 |
| 24-04-25 | 8.48 | +2.91% | 3,367,600 |
| 24-04-24 | 8.24 | +1.48% | 2,452,800 |
| 24-04-23 | 8.12 | +2.01% | 2,937,700 |
| 24-04-22 | 7.96 | +2.98% | 3,416,395 |
End-of-day quote Shanghai S.E., April 25, 2024
More quotes
Tibet Weixinkang Medicine Co., Ltd. is a China-based company principally engaged in the research and development, production and sales of chemical medicines and related active pharmaceutical ingredients (APIs). The Company's main products include injection of complex vitamins, injection of potassium aspartate magnesium, sucrose iron injection and potassium aspartate injection. The Company is also engaged in the production and sales of liver protection drugs and antibiotics products. The Company mainly distributes its products in the domestic market.
Sector
Pharmaceuticals
Calendar
2024-08-28
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -16.01% | 526M | |
| +19.62% | 43.34B | |
| +20.44% | 21.96B | |
| +10.86% | 14.09B | |
| +13.07% | 13.64B | |
| +37.46% | 11.43B | |
| -8.59% | 6.86B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +8.46% | 5.22B |
- Stock Market
- Equities
- 603676 Stock
